The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Zymeworks Receives FDA Fast Track Designation for Ovarian Cancer Treatment ZW191

A medical device with a screen displaying 'Pivot' and data, glowing green, against an orange background with faded FDA, HHS, and validation logos, plus digital charts.

Key Facts

1The U.S. FDA granted Fast Track designation to Zymeworks' ZW191 drug candidate.

Zymeworks Inc. (ZYME) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug candidate, ZW191. The drug is an antibody-drug conjugate (ADC) specifically designed to target folate receptor-alpha (FRα) in patients with advanced or metastatic platinum-resistant ovarian cancer (PROC). This designation is intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill unmet medical needs. By receiving Fast Track status, Zymeworks may benefit from more frequent interactions with the FDA and potential eligibility for accelerated approval. This regulatory milestone is viewed as a positive development for the company's oncology pipeline, typically boosting investor confidence in its long-term commercial prospects. The announcement underscores the company's progress in advancing targeted therapies for difficult-to-treat cancers.